Latest news and press releases about GH Research PLC (GHRS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD).
Price
| Price | $27.75 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | IE |
Valuation Ratios
| Price / Book | 5.14 |
| EV / EBITDA | -25.02 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -20.86% |
| Return on Invested Capital | -19.85% |
| Return on Assets | -16.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABUS · KURA · LENZ · NBTX · PROK · PVLA · RZLT
Explore sector: Healthcare · Biotechnology
More sections of GHRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks